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Abstract Poly(ADP-ribose) polymerase-1 (PARP1) is a
key facilitator of DNA repair. PARP inhibitors have gained
recent attention as promising therapeutic agents for the
treatment of solid tumours including breast cancer (BC).
However, the biological and clinical significance of PARP1
expression in BC and its role in DNA-damage response
(DDR) remain to be defined. We investigated the expres-
sion of PARP1 expression, cleaved (PARP1c) and non-
cleaved (PAR1nc) forms, in a large and well-characterised
cohort of clinically annotated stage I–III operable BCs
(n = 1,269) and 43 BRCA1-mutated BCs using immuno-
histochemistry. PARP1 expression was correlated to clin-
icopathological variables, outcome and expression of other
key DNA repair proteins (BRCA1, RAD51, Ku70/80,
PIASc and CHK1). Expression of PARP1 was exclusively
nuclear. 49 and 85 % of sporadic BC showed expression
PARP1nc and PARP1c, respectively. In BRCA1-mutated
tumours, PARP1nc/PARP1c was highly expressed (95 and
79 %, respectively). PARP1nc expression was positively
associated with premenopausal younger age patients, larger
size and higher tumour grade. PARP1 was positively
associated with DDR-proteins; RAD51, BRCA1, CHK1
and PIASc (p \ 0.001). Negative association was found
between PARP1nc and Ki67. PARP1c was associated with
ER (p \ 0.001). Different associations between PARP1
and DDR-proteins were observed when stratified based on
ER/BRCA1 status. PARP1 was not an independent pre-
dictor of outcome in sporadic or BRCA1-mutated BC. Our
results demonstrate a potential biological role for PARP1c
and PARP1nc in DNA repair in BC based on the significant
association with other key DNA damage repair proteins.
These associations were not restricted to ER-negative or
triple-negative subgroup.
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Introduction
DNA repair pathways play key roles in maintaining geno-
mic stability and influence carcinogenesis and tumour
biology. Impaired DNA repair also impacts upon response
to DNA damaging radiotherapy and chemotherapeutics [1].
Poly[ADP-ribose] polymerase (PARP) is a key DNA repair
factor. PARP is an abundant, highly conserved, cell sig-
nalling protein that exclusively catalyses poly ADP-ribo-
sylation of DNA-binding proteins, thereby modulating their
activity. PARP is essential for DNA single strand break
(SSB) repair [2], a sub-pathway related to base excision
repair. Loss of PARP are associated persistent SSBs that get
converted to DNA double-strand breaks (DSBs) following
collapse of replication forks. DSBs generated during the
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S-phase of the cell cycle is repaired via homologous
recombination (HR) pathway whereas DSBs generated
outside the S-phase are processed through the error-prone
non-homologous end joining (NHEJ) repair pathway.
PARP1 is also involved in HR and NHEJ pathways [3–5].
The BRCA genes encode BRCT repeat containing pro-
teins that facilitate the efficient resolution of DSBs gener-
ated during the S-phase through HR. Cells lacking
functional BRCA proteins are deficient in HR, and thus
dependent on the more error-prone NHEJ pathway. This
transition results in chromosomal instability and drive a
malignant phenotype. Women carrying deleterious germ-
line mutations in the BRCA1 and BRCA2 genes have a
high risk of developing breast and ovarian cancers. It was
recently demonstrated that HR impaired BRCA deficient
cells are hypersensitive to PARP inhibitors. Although the
precise mechanism for synthetic lethality is not fully
known, SSB repair inhibition may result in the formation
and accumulation of toxic DSBs at replication forks in
BRCA deficient cells and induces synthetic lethality.
Emerging data from clinical trials using PARP inhibitors in
BRCA deficient breast and ovarian tumours has provided
promising evidence that synthetic lethality by targeting
PARP has clinical potential [6–9].
PARP1 is the main member of the PARP family. PARP1
induce cell survival through DNA repair; however during
apoptosis, PARP1 is cleaved into two fragments by casp-
ases resulting in its inactivation [10]. This caspase-medi-
ated PARP1 inactivation suggests that blocking PARP1
activity is vital for the proper function of the apoptotic
machinery by the ensuing DNA fragmentation [11].
Although overexpression of PARP1 is found in different
primary human tumours compared to normal tissue coun-
terparts [12–14], the biological and clinical significance of
PARP1 protein expression in breast cancer remains to be
fully elucidated. In this study we have assessed the
expression of PARP1 (both cleaved and non-cleaved
forms) in a large and well-characterised clinically anno-
tated series of breast cancer with a long term follow-up
data. Its association with clinicopathological variable,
molecular variables and patients outcome was evaluated.
Materials and methods
Study patients
This retrospective study was conducted using two inde-
pendent cohorts of patients; an initial biomarker discovery
cohort consisting of 1902 ER-negative and ER-positive
patients and a control cohort of 43 breast cancer from
patients with confirmed BRCA1-germline mutations. The
discovery cohort comprises a well-characterised
consecutive series of early stage (TNM Stage I–III) sporadic
primary operable invasive breast carcinoma from patients
(age B70 years) enrolled into the Nottingham Tenovus
Primary Breast Carcinoma Series that presented at Not-
tingham City Hospital between 1989 and 2004 (n = 1,502)
and managed in accordance to a uniform protocol. Patients’
clinical history, tumour characteristics, information on
therapy and outcomes are prospectively maintained. Out-
come data include survival status, survival time, cause of
death and development and time to local and regional
recurrence and distant metastasis (DM). Breast cancer spe-
cific survival (BCSS) is defined as the time (in months) from
the date of primary surgery to the date of breast cancer-
related death. Disease free survival (DFI) is defined as the
time (in months) from the date of primary surgery to the
appearance of a recurrence. In this study, overall relapse free
survival was not considered in the analysis as the develop-
ment of locoregional recurrence is influenced by local
management factors and tumour stage, which may confound
the effect of the primary tumour biology.
Tissue arrays and immunohistochemistry
Tumour samples were arrayed as previously described
[15]. In brief, tissue cores with a diameter of 0.6 mm were
punched from the representative tumour regions of each
donor block. Cores were precisely arrayed into a new
recipient paraffin blocks (TMA) using a tissue microarrayer
(Beecher Instruments). Immunohistochemical staining was
performed on 4 lm thick sections using Novolink polymer
detection system (Leica Biosystems, RE7150-K), com-
posed of Peroxidase Block, Post Primary Block, Novolink
Polymer, DAB chromogen and substrate buffer and Nov-
olink haematoxylin. Table 1 shows the dilution, source and
clone of antibodies used in this study. Briefly, tissue slides
were deparaffinised with xylene and rehydrated through 3
changes of alcohol. Antigen retrieval (except for EGFR and
HER2) was performed in citrate buffer (pH 6.0) for 20 min
using a microwave oven. Endogenous peroxidase activity
was blocked by Peroxidase Block for 5 min. Slides were
washed with Tris-Buffered Saline (TBS, pH 7.6), followed
by application of Protein Block for 5 min. Following
another TBS wash, primary antibody, optimally diluted in
Leica antibody diluent (RE7133), was applied and incu-
bated for 60 min. Slides were washed with TBS followed
by incubation with Post Primary Block for 30 min followed
by a TBS wash. Novolink polymer was applied for 30 min.
DAB working solution made up of 1:20 DAB chromogen
in DAB substrate buffer was prepared and applied for
5 min. Slides were counterstained with Novolink haema-
toxylin for 6 min, dehydrated and coverslipped. Negative
(omission of the primary antibody) and Positive controls
were included according to manufacturer datasheet of each
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antibody. Table 1 shows the different biomarkers included
in this study. Antibody specificity was tested using Western
blotting and correct sized band was obtained for the dif-
ferent proteins. HER2 status was also confirmed using
in situ hybridisation in borderline cases. Ki67 was assessed
using full face section as previously described [17].
Evaluation of immunohistochemical staining
Two cores were evaluated from each tumour. Each core
was scored individually and the mean of the two readings
was calculated. If one core was uninformative, the overall
score applied was that of the remaining core. Assessment
of staining was based on a semi-quantitative approach
using a modified histochemical score (H-score) was used
which includes an assessment of both the intensity of
staining and the percentage of stained cells [16]. For the
intensity, a score index of 0, 1, 2 and 3 corresponding to
negative, weak, moderate and strong staining intensity was
used and the percentage of positive cells at each intensity
was estimated subjectively. A final score of 0–300 is the
product of both the intensity and the percentage. Cut-off of
expression of PARP1 and ID4 was chosen based on the
median: H-score of 200 for PARP1 cleaved (PARP1c) and
Table 1 Source, dilution and pre-treatment of antibodies used
Antibody Dilution Source/clone Pretreatment/solution Cut-off
Hormone receptor
ERa 1:200 DAKO, ID5 Microwave, citrate pH 6.0 C1 %
DNA damage repair molecules
PARP1 (Cleaved) 1:1,000 Abnova, A6.4.12 Microwave, citrate pH 6.0 [200 H-score
PARP1 (Non-cleaved) 1:1,000 BD Pharmingen, 7D3-6 Microwave, citrate pH 6.0 [10 H-score
RAD51 1:70 Abcam, mouse polyclonal Microwave, citrate pH 6.0
BRCA1 1:150 Oncogene research, MS110 Microwave, citrate pH 6.0 [100 H-score
Ku70/Ku80 1:2,500 Abcam, mouse monoclonal Microwave, citrate pH 6.0 [90 H-score
PIASc 1:50 Abcam, anti E3 (ab61405) Microwave, citrate pH 6.0 [160 H-score
BRCA1 transcriptional suppressor molecule
ID4 1:300 Abcam, ab 20988- 100 Microwave, citrate pH 6.0 [12 H-score
EGFR family members
EGFR 1:30 Zymed, 31G7 Proteinase K [10 %
c-erbB-2 (HER2) 1:250 DAKO, c-erbB-2 None 3? (2? with CISH)
Cell cycle, proliferation and apoptosis related proteins
p53 1:50 Novocstra, DO7 Microwave, citrate pH 6.0 [10 %
MDM2 1:50 Novocastra, IB10 Microwave, citrate pH 6.0 C10 %
Ki-67/clone MIB1a 1:100 DAKO, M7240 Microwave, citrate pH 6.0 [10 %
Bcl2 1:100 DAKO, 124 Microwave, citrate pH 6.0 [10 %
CHK1 1:150 Abcam, rabbit polyclonal Microwave, citrate pH 6.0 [30 H-score
CK5/6 1:100 Boehringer biochemica, D5/16134 Microwave, citrate pH 6.0 [10 %
CK14 1:100 Novocastra, LL002 Microwave, citrate pH 6.0 [10 %
CK17 1:20 Abcam, E3 Microwave, citrate pH 6.0 [10 %
a Performed on full face formalin fixed, paraffin embedded tissue sections
Fig. 1 Expression of a PARP1 non-cleaved b PARP1 cleaved protein
expression. Normal breast tissue showing weak expression with
tumour showing strong expression 920
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10 for PARP1 non-cleaved (PARP1nc). Cut-offs of the
other biomarkers included in this study (Table 1) were
chosen as per previous publications [17–19].
Statistical analysis
Statistical analysis was performed using SPSS 21.0 statis-
tical software. Univariate and multivariate analyses were
performed by Chi-squared test, Log rank and Cox regres-
sion analysis, respectively. Survival curves were analysed
by the method of Kaplan–Meier (Kaplan and Meier, 1958).
A p value \ 0.01 was considered significant. This study
complied with reporting recommendations for tumour
marker prognostic studies (REMARK) criteria.
Results
In this study, the expression of PARP1 protein including
the non-cleaved/active (PARP1nc) and the cleaved
Fig. 2 Cell cycle regulators
(p21 and p27), BRCA1
transcriptional suppressor
marker (ID4) and DNA repair
proteins [PARP1 (cleaved),
RAD51, Ku70/80, PIASc and
CHK1] immunohistochemical
expressions in invasive breast
carcinomas: a P21 positive IHC
expression, b P27 positive IHC
expression, c ID4 positive IHC
expression, d PARP1 (cleaved)
positive IHC expression,
e RAD51 positive IHC
expression, f Ku70/80 positive
IHC expression, g PIASc
positive IHC expression and
h CHK1 positive IHC
expression (9400)
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(PARP1c) forms were assessed immunohistochemically
and correlated with clinicopathological variables, expres-
sion of key biomarkers with relevance to breast cancer,
DNA repair markers and patient outcome. Both PARP1
protein forms (PARP1c and PARP1nc) were observed only
in the nuclei with no cytoplasmic or membranous expres-
sion. Expression of PARP1c and PARP1nc were observed
in the normal parenchymal cells of the entrapped normal
tissue but their expression was upregulated in malignant
cells (Fig. 1). Only nuclear expression in the malignant
cells was considered in this study Fig. 2.
In unselected sporadic breast cancer, reduced or absent
expression of PARP1c was observed in 15.4 % while
negative expression of PARP1nc (active form) was
observed in 51.3 % (Table 2). There was a highly signifi-
cant correlation between both proteins (p \ 0.001).
PARP1nc was negative in 2/43 (4.7 %) BRCA1 germline-
mutated tumours whereas PARP1c was negative in 5/43
(10.4 %, Table 2) tumours.
Association with clinicopathological and molecular
variables sporadic breast cancer
PARP1nc
PARP1nc expression was positively associated with pre-
menopausal younger age patients and higher tumour grade
with nuclear pleomorphism, mitosis and a poorer prognosis
(Table 3). There was no association with histological
tumour type, vascular invasion, size or stage.
Expression of PARP1nc showed positive association
with the expression of other DNA repair proteins involved
in DDR (BRCA1, RAD51, check-point proteins, (CHK1
and CHK2) PIASc and DNA PK), together with the pro-
liferation marker Ki67 and p53 (Table 4). No association
was observed with ER, HER2, the BRCA1 transcriptional
suppressor ID4, BARD1, BRCA2, Ku70/Ku80 or APE1.
Although there was a positive association between
PARP1nc and BRCA1, both proteins showed opposite
association with proliferation and with other DNA repair
proteins; the majority of PARP1nc?/BRCA1- was asso-
ciated with high expression of DNA PK (p = 0.003), p53
(p \ 0.001), and ki67 (p \ 0.001) compared with
PARP1nc-/BRCA1? tumours (Table 5). Positive CHK1
expression (p = 0.004) and negative expression of PIASc
(p = 0.013) were associated with PARP1nc-/BRCA1?
tumours.
When the series was classified based on ER expression,
positive correlations between PARP1nc and PIASc, DNA-
PKcs and p53 were seen in both ER ? and ER- tumours
while positive associations with BRCA1, RAD51, CHK1
and CHK2 were seen only in ER? but not in the ER-
tumours (Table 6). In ER- tumours, associations between
PARP1nc and ki67 (positive) and ID4 (negative) were
observed but not in the ER? tumours.
In triple-negative tumour, PARP1nc was positively
associated with expression of PIASc (p = 0.002) and p53
(p = 0.022, Table 7). No association with the expression
of the other markers was found.
PARP1c
PARP1c expression was positively associated with the
expression of ER, non Triple-Negative tumour (Table 2)
and DDR proteins including RAD51, Ku70/80, CHK1,
CHK2, DNA-PKcs, and PIASc (Table 4). No association
was observed with the clinicopathological variables
(Table 3), expression of other DDR proteins (BRCA1,
BRCA2, ID4, BARD1 and APE1), HER2, p53, Ki67 or
basal phenotype (Tables 3, 4).
Table 2 Immunohistochemical
expression of PARP1 cleaved




ER oestrogen receptor, NS not
significant
PARP1 non-cleaved n (%) PARP1 cleaved n (%)
Negative Positive p value Negative Positive p value
Unselected sporadic series 552 (51.3) 524 (48.7) N/A 194 (15.4) 1075 (84.6) N/A
BRCA1-mutated tumours 2 (4.7) 41 (95.3) 5 (10.4) 38 (79.2)
Classes
ER Negative 140 (49.6) 142 (50.4) NS 59 (18.9) 253 (81.1) 0.041
Positive 405 (51.7) 379 (48.3) 134 (14.1) 815 (85.9)
HER2 Negative 469 (52.1) 432 (47.9) NS 165 (15.3) 913 (84.7) NS
Positive 63 (46.3) 73 (53.7) 22 (14.0) 135 (86.0)
Triple negative No 446 (52.1) 410 (47.9) NS 145 (14.1) 883 (85.9) 0.030
Yes 90 (47.6) 99 (52.4) 42 (20.0) 168 (80.0)
Basal phenotype No 414 (52.0) 382 (48.0) NS 141 (14.8) 810 (85.2) NS
Yes 138 (48.9) 132 (51.1) 53 (16.8) 263 (83.2)
Breast Cancer Res Treat (2015) 149:353–362 357
123
When the series was classified based on ER expression,
the correlation between PARP1c, and RAD51, PIASc and
DNA-PKcs was seen in both ER? and ER- cohorts while
its associations with CHK1 and p53 were seen only in
ER? but not in the ER- subgroups (Table 6). No associa-
tion with PARP1c was seen in the ER- subgroup only. In the
triple-negative tumour, PARP1c showed positive associa-
tion with the expression of PIASc and DNA-PKcs (Table 7).
Combined expression of PARP1nc and PARP1c showed a
positive association between PARP1nc ?/PARP1c ? tumours
and BRCA1 nuclear (p = 0.027), CHK1 (p \ 0.001), DNA-
PKcs (p \ 0.001), PIASc (p \ 0.001) and p53 (p \ 0.001)
expression and between PARP1nc-/PARP1c? tumours and
APE1 (p = 0.016) and KU70/KU80 (p \ 0.001)
expression.
Association with patient outcome
Although no association between PARP1 and patient out-
come (BCSS or DFI) was observed in the sporadic breast
cancer series or in subgroups based on ER, an association
was identified when PARP1nc was combined with BRCA1
Table 3 Relationship between

















Pre 182 (33.2) 216 (41.7) 0.004 65 (33.5) 409 (38.5) NS
Post 366 (66.8) 302 (58.3) 129 (66.5) 653 (61.5)
Age
\50 163 (29.7) 193 (36.9) 0.012 61 (31.4) 365 (34) NS
C50 386 (70.3) 330 (63.1) 133 (68.6) 710 (66)
Tumour size
B2 cm 279 (51.2) 240 (46.1) NS 96 (50) 523 (48.8) NS
[2 cm 266 (48.8) 281 (53.9) 96 (50) 548 (51.2)
Tumour stage
1 346 (62.9) 310 (59.5) NS 129 (66.5) 634 (59.2) NS
2 159 (28.9) 164 (31.5) 51 (26.3) 342 (31.9)
3 45 (8.2) 47 (9.0) 14 (7.2) 95 (8.9)
Tumour grade
1 113 (20.7) 69 (13.3) 0.001 32 (16.7) 180 (17.9) NS
2 180 (33) 163 (31.3) 61 (31.8) 368 (34.5)
3 253 (46.3) 288 (55.4) 99 (51.6) 519 (48.6)
Tubule formation
1 35 (6.7) 24 (4.7) NS 11 (5.9) 62 (6) NS
2 181 (34.6) 160 (31.6) 57 (30.3) 336 (32.6)
3 307 (58.7) 323 (63.7) 120 (63.8) 634 (61.4)
Pleomorphism
1 14 (2.7) 10 (2) <0.001 1 (0.5) 29 (2.8) NS
2 233 (44.6) 168 (33.1) 76 (40.4) 404 (39.2)
3 275 (52.7) 329 (64.9) 111 (59) 598 (58)
Mitosis
1 201 (38.4) 145 (28.6) 0.001 66 (35.1) 373 (36.1) NS
2 103 (19.7) 95 (18.7) 30 (16) 200 (19.4)
3 219 (41.9) 267 (52.7) 92 (48.9) 459 (44.5)
Vascular invasion
Negative 185 (34) 174 (33.5) NS 65 (34) 355 (33.2) NS
Positive 359 (66) 346 (66.5) 126 (66) 714 (66.8)
NPI groups
Good 190 (34.9) 134 (25.7) 0.005 63 (32.8) 326 (30.4) NS
Moderate 269 (49.4) 295 (56.6) 94 (49) 566 (52.8)
Poor 86 (15.8) 92 (17.7) 35 (18.2) 179 (16.7)
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(V2 = 13.8, p = 0.003). The association between
PARP1nc and DFI in the context of BRCA1 expression
was observed in BRCA1-positive tumours (V2 = 5.4,
p = 0.020) (Fig. 3) but not in the BRCA1-negative
tumours. There were no significant associations between
PARP1 expression and patient outcome according to sys-
temic treatment.
Discussion
This study investigated the expression levels of PARP1 in
breast cancer using immunohistochemistry. Our main aim
was to better understand the biological role of PARP1 with
particular emphasis on DNA repair mechanisms and in the
different subgroups of breast cancer. We found that
PARP1nc expression was increased in BRCA1-mutated
tumours compared with invasive sporadic breast cancer.
PARP1nc was also correlated with BRCA1 protein
expression in sporadic tumours. High nuclear PARP1,
incorporating both the cleaved and non-cleaved expression,
is found in the majority of BRCA1-associated BCs which
is similar to that observed in our study [20]. Conversely,
we have previously shown PARP1nc is relatively low in
BRCA1-protein deficient ovarian high grade serous carci-
noma [21].
Table 4 Relationship between
PARP1 cleaved and non-















APE1 Negative 31 (16.2) 36 (15.9) NS 16 (19.8) 59 (14.4) NS
Positive 160 (83.8) 190 (84.1) 65 (80.2) 352 (85.6)
BARD1 Negative 299 (87.4) 314 (88.2) NS 115 (89.8) 620 (86.8) NS
Positive 43 (12.6) 42 (11.8) 13 (10.2) 86 (12.2)
BRCA1 Negative 218 (51.8) 178 (41.9) 0.004 74 (50.3) 370 (43.3) NS
Positive 203 (48.2) 247 (58.1) 73 (49.7) 485 (56.7)
BRCA2 Negative 348 (92.6) 333 (92.5) NS 111 (92.5) 666 (92.4) NS
Positive 28 (7.4) 27 (7.5) 9 (7.5) 55 (7.6)
RAD51 Negative 275 (68.9) 191 (48.1) <0.001 107 (84.3) 391 (53.8) <0.001
Positive 124 (31.1) 206 (51.9) 20 (15.7) 336 (46.2)
CHK1 Negative 360 (79.3) 323 (69.3) <0.001 127 (84.7) 607 (71.9) <0.001
Positive 94 (20.7) 143 (30.7) 23 (15.3) 237 (28.1)
Ku70/Ku80 Negative 78 (17.3) 65 (14.6) NS 61 (38.4) 101 (12.5) <0.001
Positive 373 (82.7) 379 (85.4) 98 (61.6) 708 (87.5)
PIASc Negative 156 (33.3) 74 (15.7) <0.001 80 (50) 164 (18.3) <0.001
Positive 113 (66.7) 396 (84.3) 80 (50) 730 (81.7)
DNA-PKcs Negative 81 (25.9) 38 (11.3) <0.001 44 (36.7) 88 (13.8) <0.001
Positive 232 (74.1) 299 (88.7) 76 (63.3) 552 (86.2)
Ki67 Negative 145 (35.5) 122 (28.2) 0.022 49 (33.6) 284 (33.1) NS
Positive 263 (64.5) 311 (71.8) 97 (66.4) 573 (66.9)
ID4 Negative 424 (87.4) 410 (89.5) NS 148 (85.1) 839 (89.4) NS
Positive 61 (12.6) 48 (10.5) 26 (14.9) 99 (10.6)
P53 Negative 413 (77.1) 328 (65.3) <0.001 137 (75.3) 748 (71.2) NS
Positive 123 (22.9) 174 (34.7) 45 (24.7) 302 (28.8)







CHK1 Negative 137 (52.3) 125 (47.7) 0.004
Positive 21 (32.3) 44 (67.7)
DNA-
PKcs
Negative 12 (32.4) 25 (67.6) 0.003
Positive 116 (59.2) 80 (40.8)
P53 Negative 99 (37.1) 168 (62.9) <0.001
Positive 78 (69.0) 25 (31.0)
PIASc Negative 25 (36.2) 44 (63.8) 0.013
Positive 143 (53.0) 127 (47.0)
Ki67 Negative 25 (29.8) 59 (70.2) <0.001
Positive 130 (61.3) 82 (47.6)
Bold values indicate significance
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Table 6 Relationship between
DNA repair biomarkers
PARP1ceaved and non-cleaved















BRCA1 Negative 138 (44.5) 105 (33.9) 0.007 80 (72.1) 73 (64) NS
Positive 172 (55.5) 205 (66.1) 31 (27.9) 41 (36)
RAD51 Negative 197 (67) 113 (39.9) <0.001 77 (75.5) 78 (69.6) NS
Positive 97 (33) 170 (60.1) 25 (24.5) 34 (30.4)
CHK1 Negative 256 (77.3) 216 (64.1) <0.001 102 (85) 106 (83.5) NS
Positive 75 (22.7) 121 (35.9) 18 (15) 21 (16.5)
CHK2 Negative 135 (57.4) 94 (39.8) <0.001 66 (64.1) 54 (53.5) NS
Positive 100 (42.6) 142 (60.2) 37 (35.9) 47 (46.5)
PIASc Negative 111 (32.5) 48 (14.3) <0.001 45 (36) 26 (19.7) 0.003
Positive 231 (67.5) 288 (85.7) 80 (64) 106 (80.3)
DNA-PKcs Negative 58 (26) 25 (10.5) <0.001 23 (25.8) 13 (13.3) 0.029
Positive 165 (74) 214 (89.5) 66 (74.2) 85 (86.7)
Ki67 Negative 126 (42.3) 114 (36.4) NS 18 (16.7) 8 (6.7) 0.019
Positive 172 (57.7) 199 (63.6) 90 (83.3) 111 (93.3)
ID4 Negative 323 (91.2) 302 (90.1) NS 98 (77.2) 106 (87.6) 0.031
Positive 31 (8.8) 33 (9.9) 29 (22.8) 15 (12.4)
P53 Negative 339 (85.2) 277 (75.7) 0.001 73 (53.3) 51 (37.5) 0.009
Positive 59 (14.8) 89 (24.3) 64 (46.7) 85 (62.5)
PARP1 cleaved
RAD51 Negative 70 (81.4) 264 (49.1) <0.001 37 (90.2) 126 (68.9) 0.010
Positive 16 (18.6) 274 (50.9) 4 (9.8) 57 (31.1)
CHK1 Negative 85 (82.5) 428 (67.9) 0.003 42 (89.4) 175 (84.1) NS
Positive 18 (17.5) 202 (32.1) 5 (10.6) 33 (15.9)
CHK2 Negative 52 (66.7) 214 (45.2) <0.001 27 (61.4) 106 (58.9) NS
Positive 26 (33.3) 259 (54.8) 17 (38.6) 75 (41.1)
PIASc Negative 55 (50.9) 113 (17) <0.001 25 (48.1) 51 (22.9) <0.001
Positive 53 (49.1) 552 (83) 27 (51.9) 172 (77.1)
DNA-PKcs Negative 26 (34.2) 65 (13.6) <0.001 18 (40.9) 23 (14.3) <0.001
Positive 50 (65.8) 413 (86.4) 26 (59.1) 138 (85.7)
P53 Negative 112 (87.5) 637 (79.8) 0.040 25 (46.3) 108 (43.4) NS
Positive 16 (12.5) 161 (20.2) 29 (53.7) 141 (56.6)
Table 7 Relationship between
PARP1 cleaved and non-
















PIASc Negative 35 (42.7) 19 (20.7) 0.002 19 (51.4) 38 (25) 0.002
Positive 47 (57.3) 73 (79.3) 18 (48.6) 114 (75)
DNA-PKcs Negative 15 (25.9) 10 (15.2) NS 12 (41.4) 16 (14.4) 0.001
Positive 43 (74.1) 56 (84.8) 17 (58.6) 95 (85.6)
P53 Negative 48 (54.5) 37 (37.8) 0.022 18 (45) 71 (42.5) NS
Positive 40 (45.5) 61 (62.2) 22 (55) 96 (57.5)
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Inherent defects in DNA repair pathways represent a
common feature characterising susceptibility to PARP
inhibitors [22, 23]. This observation was consistent with
the hypothesis that loss of one critical DNA repair path-
way, such as defect in the HR-pathway in the BRCA-
mutated hereditary breast cancer, can be compensated by
upregulation of the other double-strand DNA repair
mechanisms, namely NHEJ or alternative pathway
involved in single-stand DNA repair mechanisms including
nucleotide (NER) and base (BER) excision repair. Some
authors [24, 25] have therefore postulated that when the
BRCA-dependent HR, is lost or dysfunctional, repair shifts
toward alternate DNA repair mechanisms which are
dependent on PARPs. This hypothesis was also supported
by the study of Wang et al. [26], who demonstrated that
PARP1 downregulates BRCA2 gene expression and the
study of Ossovskaya et al. [12] who found an inverse
relationship between PARP1 and BRCA1 expression in a
subset of ovarian cancer. However, current evidence indi-
cates that the specific driver of PARP1 expression in breast
cancer still unknown. The application of PARP inhibitors
to a subset of sporadic breast cancer namely triple-negative
class, was mainly based on (1) the morphologic and
molecular similarities between these tumours and BRCA1-
mutated breast cancers, and (2) the results from preclinical
studies demonstrating sensitivity to PARP inhibition in
tumours characterised by deficient HR but not by active
PARP DNA related pathways or functional status of PARP
proteins [22, 25]. Interestingly, our observation in the
BRCA1-mutated tumours support the hypothesis that in
tumours with defective HR pathways, the expression of
PARP1 proteins are upregulated.
However, the expression in the sporadic tumours
appeared to be different with positive correlation between
PARP1 and most of the other DNA repair proteins. These
findings were also observed in the different molecular
subclasses of breast cancer including triple-negative
tumour. Our findings in addition to the cytoplasmic
expression of some DNA repair genes may reflect the
complex mechanism of DNA damage repair in sporadic
tumours. Consistent with our findings, it has been reported
that transfection of the BRCA1-mutated cell line with wild-
type BRCA1 resulted in a significant increase in BER,
whereas knock-down of BRCA1 resulted in decreased BER
[27, 28].
Consistent with our study, associations between PARP1
and PIASc [29] and Ku70/80 [30, 31] have been reported.
Another important observation in our study was the lack of
association between PARP1 and HER2 and basal-associ-
ated marker expression in breast cancer.
It is reported that PARP1c is not active as the protein
undergoes apoptotic/necrotic cleavage (caspase cleavage)
and that PARP1 cleavage is a hallmark of apoptosis [32].
However, our results indicate that PARP1c plays an active
role in DNA repair with significant association with other
DNA repair proteins. This is consistent with a recent study
which demonstrated other physiological functions for the
cleaved form [33].
Although PARP1 has been thoroughly investigated and
its role in the repair of DNA break is well documented, a
model representing its exact role and placing this enzyme
in a network with other known DNA damage repair
mechanisms remains unavailable. Our results demonstrate
that expression of PARP1 proteins are associated with the
expression of other DNA repair proteins involved in both
HR and NHEJ mechanisms in addition to other markers
involved in check-point control and cell proliferation. Our
findings also indicate that the association between different
DNA damage repair proteins is observed in ER-negative
and ER-positive breast cancer suggesting variable activity
of the different mechanisms of DNA damage repair in
these tumours. Unlike BRCA1, RAD51 and ID4, no
association was observed between PARP1 and basal-
phenotype in breast cancer [34]). This lack of association
was seen in the whole series as well as in ER-negative and
ER-positive tumours. Importantly, if PARP inhibitors are
possibly targeting PARP1 proteins, other subsets of spo-
radic breast cancer rather than basal-like triple-negative
class may be potential candidate for this promising therapy.
In conclusion, our results demonstrate the biological
role of both forms of PARP1 (cleaved and non-cleaved) in




Fig. 3 Kaplan–Meier curve for DMFS with respect to PARP1 (non-
cleaved) expression in the BRCA1 positive-tumours
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association with other key DNA damage repair proteins.
These associations were not restricted to ER-negative or
triple-negative subgroup. This study also emphasises the
fact that the mechanisms controlling DNA repair in spo-
radic breast cancer are complex particularly among the
different molecular classes of sporadic breast cancer;
emphasising the need for further investigation for the target
gene that can be used as predictor for PARP inhibitors.
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